



## Humalog<sup>®</sup> (insulin lispro) – First-time generic (authorized generic)

- On March 4, 2019, [Eli Lilly announced](#) that they would be launching an authorized generic (AG) version of their [Humalog \(insulin lispro\)](#) 100 units/mL injection.
  - The AG will be made available through an Eli Lilly subsidiary, ImClone Systems.
  - The AG will be available as the 10 mL vial and 3 mL KwikPen<sup>®</sup>.
  - Eli Lilly is working with supply chain partners to make the AG available in pharmacies as quickly as possible.
- Humalog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Humalog 100 units/mL is also available in 3 mL vials, a 3 mL Junior KwikPen and 3 mL cartridges. Humalog 200 units/mL is available in a 3 mL KwikPen. [Humalog Mix75/25 \(insulin lispro protamine and insulin lispro\)](#) and [Humalog Mix50/50](#) are available in 10 mL vials and 3 mL KwikPens.
- According to Eli Lilly, the AG version will have a list price 50% lower than the current Humalog list price.
  - The list price of a single vial will be \$137.35. The list price of a five-pack of KwikPens will be \$265.20.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.